Insmed INSM AstraZeneca milestone — Intangible Amortization

Similar metrics at other companies

CPR

CPRXAmortization Expenses Of Intangible Asset

$9.7M+3.8%

MLKNAcquired Intangible Amortization

$5.8M-7.9%

LGNDDevelopment and Licensing of Biopharmaceutical Assets — Amortization of intangibles

$8.1M-1.9%

PDFSAmortization Of Intangible Assets Including Cost Of Amortization

$2.06M+94.8%

OPKPharmaceutical — Intangible Amortization

$16.44M+0.1%

SLMAcquired intangible assets amortization expense

$740K-27.5%

Questions, answered.

What is Insmed's astrazeneca milestone — intangible amortization?

Insmed (INSM) reported astrazeneca milestone — intangible amortization of $818K in Q1 2026.

What does astrazeneca milestone — intangible amortization mean?

This represents the periodic non-cash expense recognized to allocate the cost of intangible assets acquired through AstraZeneca milestones over their estimated useful lives. It reflects the systematic consumption of the economic benefits associated with these specific licensed assets. Monitoring this expense is essential for understanding the impact of acquired technology on the company's reported operating profitability.